ArticlePloS one2019

Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.

Birgit Spiess et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.